BACKGROUND: Frailty is a construct developed to characterize a state of reduced functional capacity in older adults. However, there are limited data describing the prevalence or consequences of frailty in middle-aged patients with chronic kidney disease (CKD). STUDY DESIGN: Observational study. SETTING & PARTICIPANTS: 336 non-dialysis-dependent patients with stages 1-4 CKD with estimated glomerular filtration rate (eGFR) <90 mL/min/1.73 m(2) (by the CKD-EPI [CKD Epidemiology Collaboration] serum creatinine-based equation) or evidence of microalbuminuria enrolled in the Seattle Kidney Study, a clinic-based cohort study. Findings were compared with community-dwelling older adults in the Cardiovascular Health Study. OUTCOME: Prevalence and determinants of frailty in addition to its association with the combined outcome of all-cause mortality or renal replacement therapy. MEASUREMENTS: We defined frailty according to established criteria as 3 or more of the following characteristics: slow gait, weakness, unintentional weight loss, exhaustion, and low physical activity. We estimated kidney function using serum cystatin C concentrations (eGFR(cys)) to minimize confounding due to relationships of serum creatinine levels with muscle mass and frailty. RESULTS: The mean age of the study population was 59 years and mean eGFR(cys) was 51 mL/min/1.73 m(2). The prevalence of frailty (14.0%) was twice that of the much older non-CKD reference population (P < 0.01). The most common frailty components were physical inactivity and exhaustion. After adjustment including diabetes, eGFR(cys) categories of <30 and 30-44 mL/min/1.73 m(2) were associated with a 2.8- (95% CI, 1.3-6.3) and 2.1 (95% CI, 1.0-4.7)-fold greater prevalence of frailty compared with GFR(cys) ≥60 mL/min/1.73 m(2). There were 63 events during a median 987 days of follow-up. After adjustment, the frailty phenotype was associated with an estimated 2.5 (95% CI, 1.4-4.4)-fold greater risk of death or dialysis therapy. LIMITATIONS: Cross-sectional study design obscures inference regarding temporal relationships between CKD and frailty. CONCLUSIONS: Frailty is relatively common in middle-aged patients with CKD and is associated with lower eGFR(cys) and increased risk of death or dialysis therapy.
BACKGROUND: Frailty is a construct developed to characterize a state of reduced functional capacity in older adults. However, there are limited data describing the prevalence or consequences of frailty in middle-aged patients with chronic kidney disease (CKD). STUDY DESIGN: Observational study. SETTING & PARTICIPANTS: 336 non-dialysis-dependent patients with stages 1-4 CKD with estimated glomerular filtration rate (eGFR) <90 mL/min/1.73 m(2) (by the CKD-EPI [CKD Epidemiology Collaboration] serum creatinine-based equation) or evidence of microalbuminuria enrolled in the Seattle Kidney Study, a clinic-based cohort study. Findings were compared with community-dwelling older adults in the Cardiovascular Health Study. OUTCOME: Prevalence and determinants of frailty in addition to its association with the combined outcome of all-cause mortality or renal replacement therapy. MEASUREMENTS: We defined frailty according to established criteria as 3 or more of the following characteristics: slow gait, weakness, unintentional weight loss, exhaustion, and low physical activity. We estimated kidney function using serum cystatin C concentrations (eGFR(cys)) to minimize confounding due to relationships of serum creatinine levels with muscle mass and frailty. RESULTS: The mean age of the study population was 59 years and mean eGFR(cys) was 51 mL/min/1.73 m(2). The prevalence of frailty (14.0%) was twice that of the much older non-CKD reference population (P < 0.01). The most common frailty components were physical inactivity and exhaustion. After adjustment including diabetes, eGFR(cys) categories of <30 and 30-44 mL/min/1.73 m(2) were associated with a 2.8- (95% CI, 1.3-6.3) and 2.1 (95% CI, 1.0-4.7)-fold greater prevalence of frailty compared with GFR(cys) ≥60 mL/min/1.73 m(2). There were 63 events during a median 987 days of follow-up. After adjustment, the frailty phenotype was associated with an estimated 2.5 (95% CI, 1.4-4.4)-fold greater risk of death or dialysis therapy. LIMITATIONS: Cross-sectional study design obscures inference regarding temporal relationships between CKD and frailty. CONCLUSIONS: Frailty is relatively common in middle-aged patients with CKD and is associated with lower eGFR(cys) and increased risk of death or dialysis therapy.
Authors: Yuen-Ting Diana Kwong; Lesley A Stevens; Elizabeth Selvin; Yaping Lucy Zhang; Tom Greene; Frederick Van Lente; Andrew S Levey; Josef Coresh Journal: Am J Kidney Dis Date: 2010-07 Impact factor: 8.860
Authors: Josep Garre-Olmo; Laia Calvó-Perxas; Secundino López-Pousa; Manuel de Gracia Blanco; Joan Vilalta-Franch Journal: Age Ageing Date: 2012-03-27 Impact factor: 10.668
Authors: Kristine E Ensrud; Li-Ying Lui; Brent C Taylor; Areef Ishani; Michael G Shlipak; Katie L Stone; Jane A Cauley; Sophie A Jamal; Diana M Antoniucci; Steven R Cummings Journal: Arch Intern Med Date: 2007-01-22
Authors: L P Fried; C M Tangen; J Walston; A B Newman; C Hirsch; J Gottdiener; T Seeman; R Tracy; W J Kop; G Burke; M A McBurnie Journal: J Gerontol A Biol Sci Med Sci Date: 2001-03 Impact factor: 6.053
Authors: Alfonso J Cruz-Jentoft; Jean Pierre Baeyens; Jürgen M Bauer; Yves Boirie; Tommy Cederholm; Francesco Landi; Finbarr C Martin; Jean-Pierre Michel; Yves Rolland; Stéphane M Schneider; Eva Topinková; Maurits Vandewoude; Mauro Zamboni Journal: Age Ageing Date: 2010-04-13 Impact factor: 10.668
Authors: Carmen Castaneda; Patricia L Gordon; Russell C Parker; Katherine Leigh Uhlin; Ronenn Roubenoff; Andrew S Levey Journal: Am J Kidney Dis Date: 2004-04 Impact factor: 8.860
Authors: Ismay N van Loon; Namiko A Goto; Franciscus T J Boereboom; Michiel L Bots; Marianne C Verhaar; Marije E Hamaker Journal: Clin J Am Soc Nephrol Date: 2017-07-17 Impact factor: 8.237
Authors: Allyson Hart; Misti L Paudel; Brent C Taylor; Areef Ishani; Eric S Orwoll; Peggy M Cawthon; Kristine E Ensrud Journal: J Am Geriatr Soc Date: 2013-09-03 Impact factor: 5.562
Authors: Viji Nair; Cassianne Robinson-Cohen; Michelle R Smith; Keith A Bellovich; Zeenat Yousuf Bhat; Maria Bobadilla; Frank Brosius; Ian H de Boer; Laurent Essioux; Ivan Formentini; Crystal A Gadegbeku; Debbie Gipson; Jennifer Hawkins; Jonathan Himmelfarb; Bryan Kestenbaum; Matthias Kretzler; Maria Chiara Magnone; Kalyani Perumal; Susan Steigerwalt; Wenjun Ju; Nisha Bansal Journal: J Am Soc Nephrol Date: 2017-02-03 Impact factor: 10.121
Authors: Lorien S Dalrymple; Ronit Katz; Dena E Rifkin; David Siscovick; Anne B Newman; Linda F Fried; Mark J Sarnak; Michelle C Odden; Michael G Shlipak Journal: Clin J Am Soc Nephrol Date: 2013-10-31 Impact factor: 8.237
Authors: Cynthia Delgado; Stephanie Shieh; Barbara Grimes; Glenn M Chertow; Lorien S Dalrymple; George A Kaysen; John Kornak; Kirsten L Johansen Journal: Am J Nephrol Date: 2015-09-19 Impact factor: 3.754
Authors: Ranjani N Moorthi; Simit Doshi; Linda F Fried; Sharon M Moe; Mark J Sarnak; Suzanne Satterfield; Ann V Schwartz; Michael Shlipak; Brittney S Lange-Maia; Tamara B Harris; Anne B Newman; Elsa S Strotmeyer Journal: Nephrol Dial Transplant Date: 2019-04-01 Impact factor: 5.992